BridgeMD
Compares treatment options for Colorectal Cancer
Official title A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
ClinicalTrials.gov ID: NCT07525206
What this study is testing
What is Telisotuzumab adizutecan?
Telisotuzumab adizutecan is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for colorectal cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC).
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Must voluntarily sign and date an informed consent, approved by an Ethics Committee (IEC)/ Institutional Review Board (IRB), prior to the initiation...
- Life expectancy \>= 12 weeks per investigator assessment
You likely can't join if
- Prior systemic regimen containing c-Met targeting agent (e.g., antibody, antibody drug conjugate, bispecific) or any other unapproved investigational...
- History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients, or to compounds similar to trifluridine/tipiracil.
- History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.
- History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.
The study team makes the final eligibility decision.
Where it's taking place
- East Brunswick, New Jersey, United States
- Lake Success, New York, United States
- Seattle, Washington, United States
- Brasschaat, Antwerpen, Belgium
- Anderlecht, Brussels Capital, Belgium
- Charleroi, Hainaut, Belgium
- Ghent, Oost-Vlaanderen, Belgium
- Roeselare, West-Vlaanderen, Belgium
- Kashiwa-shi, Chiba, Japan
- Guimarães, Braga District, Portugal
- Loures, Lisbon District, Portugal
- Almada, Setúbal District, Portugal
- Lisbon, Portugal
- Porto, Portugal
- Busan, Busan Gwang Yeogsi, South Korea
- Incheon, Gyeonggido, South Korea
- Seongnam, Gyeonggido, South Korea
- Barcelona, Spain
- Madrid, Spain
- Taipei, Tainan, Taiwan
+ 4 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include East Brunswick, New Jersey, United States; Lake Success, New York, United States; Seattle, Washington, United States; Brasschaat, Antwerpen, Belgium; Anderlecht, Brussels Capital, Belgium; Charleroi, Hainaut, Belgium and 18 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.